The global market for Immunoassay for Neurological Biomarkers was estimated at US$809.9 Million in 2024 and is projected to reach US$2.1 Billion by 2030, growing at a CAGR of 17.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Immunoassay for Neurological Biomarkers market.
Global Immunoassay for Neurological Biomarkers Market - Advancing Neurodiagnostics
Why Are Immunoassays Becoming Crucial in Neurology?
Immunoassays for neurological biomarkers are gaining significant traction due to their ability to detect and quantify proteins associated with neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The rising prevalence of these conditions, coupled with an aging population, has driven demand for early and accurate diagnostic tools. Immunoassays provide a non-invasive method for detecting neurological biomarkers in blood and cerebrospinal fluid, enabling timely intervention and disease management.How Are Innovations in Immunoassay Technology Impacting the Market?
Technological advancements, including highly sensitive multiplex immunoassays and digital immunoassays, have improved the precision and scalability of neurological diagnostics. AI-driven data analysis is further refining biomarker detection, allowing for early-stage identification of neurological disorders. Moreover, the development of point-of-care immunoassay platforms is making neurodiagnostics more accessible, reducing dependency on specialized laboratory infrastructure. Portable and home-based diagnostic kits are also emerging, catering to patients who require regular monitoring.What Are the Market Growth Factors?
The growing focus on early diagnosis of neurodegenerative diseases, increasing investment in biomarker research, and rising collaborations between pharmaceutical and diagnostic companies are major growth drivers in this market. Government initiatives promoting neurological research and advancements in personalized medicine are also contributing to the rapid expansion of immunoassay applications for neurological biomarker detection. Additionally, the pharmaceutical industry is leveraging immunoassays for drug development and clinical trials, further expanding their application.What Lies Ahead for the Market?
Despite the promising growth, challenges such as regulatory hurdles, cost barriers, and standardization of biomarker panels need to be addressed. However, the increasing integration of AI, automation, and next-generation sequencing is expected to bridge these gaps. As demand for precision medicine grows, immunoassays for neurological biomarkers will play a pivotal role in transforming neurodiagnostics and patient care.Scope of Study:
The report analyzes the Immunoassay for Neurological Biomarkers market in terms of units by the following Segments, and Geographic Regions/Countries:- Segments: Product (Instruments Immunoassay for Neurological Biomarkers, Reagents Immunoassay for Neurological Biomarkers, Services Immunoassay for Neurological Biomarkers); Disease (Alzheimer`s Disease, Parkinson`s Disease, Multiple Sclerosis Disease, Other Diseases); Application (In Vitro Diagnostics Application, Research Application)
- Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Instruments Immunoassay for Neurological Biomarkers segment, which is expected to reach US$1.3 Billion by 2030 with a CAGR of a 19.4%. The Reagents Immunoassay for Neurological Biomarkers segment is also set to grow at 14.2% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $220.6 Million in 2024, and China, forecasted to grow at an impressive 23.2% CAGR to reach $474.9 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Immunoassay for Neurological Biomarkers Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Immunoassay for Neurological Biomarkers Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Immunoassay for Neurological Biomarkers Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Abbott Laboratories, ADx NeuroSciences NV, Banyan Biomarkers, Inc., bioMérieux SA, Bio-Rad Laboratories, Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 47 companies featured in this Immunoassay for Neurological Biomarkers market report include:
- Abbott Laboratories
- ADx NeuroSciences NV
- Banyan Biomarkers, Inc.
- bioMérieux SA
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation
- C2N Diagnostics
- EnCor Biotechnology Inc.
- F. Hoffmann-La Roche Ltd
- Fujirebio
- Johnson & Johnson Services, Inc.
- Merck KGaA
- Nimble Therapeutics
- PerkinElmer, Inc.
- QIAGEN N.V.
- Quanterix Corporation
- Quibim
- Siemens Healthineers AG
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
- Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- ADx NeuroSciences NV
- Banyan Biomarkers, Inc.
- bioMérieux SA
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation
- C2N Diagnostics
- EnCor Biotechnology Inc.
- F. Hoffmann-La Roche Ltd
- Fujirebio
- Johnson & Johnson Services, Inc.
- Merck KGaA
- Nimble Therapeutics
- PerkinElmer, Inc.
- QIAGEN N.V.
- Quanterix Corporation
- Quibim
- Siemens Healthineers AG
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 380 |
| Published | July 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 809.9 Million |
| Forecasted Market Value ( USD | $ 2100 Million |
| Compound Annual Growth Rate | 17.3% |
| Regions Covered | Global |
